Black patients with stage IV non-small cell lung cancer were 20 percent less likely and Hispanic patients 17 percent less likely to be enrolled in clinical trials, according to a study of 1.7 million cancer patients from 2004 to 2018.
Also less likely to participate in clinical trials were lung cancer patients with Medicaid or with no health insurance or who were treated in community cancer programs and not in academic or research programs.
The study results were presented at a 2023 scientific meeting.
- See “Disparities in Clinical Trial Enrollment Among NSCLC Patients” by Laura M. Healy on the Cancer Therapy Advisor website (May 10, 2023)
- See the meeting abstract “National enrollment of lung cancer clinical trials is disproportionate based on race and health care access” (2023)
